Nicholas Blondin, MD

• Anita Huttner
• Benjamin L. Judson
• Joseph Paul Antonios
• Joseph Piepmeier
• Joseph Schindler
• Kanat Yalcin
• Ketu Mishra-Gorur
• Mariam Aboian
• Murat Gunel
• Robert Fulbright
• Robin de Graaf
• Sacit Bulent Omay
• Tanyeri Barak
• Veronica Chiang

Nervous System Neoplasms; Neurology

• The clinical and genomic features of seizures in meningiomasDincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.
• Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastomaMellinghoff I, Alexander B, Berry D, Blondin N, Buxton M, Cavenee W, Colman H, de Groot J, de la Fuente M, Ellingson B, Gordon G, Hyddmark E, Khasraw M, Lassman A, Lee E, Li W, Lim M, Mikkelsen T, Nelli A, Perry J, Sulman E, Tanner K, Weller M, Wen P, Cloughesy T. Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Cancer Research 2023, 83: ct062-ct062. DOI: 10.1158/1538-7445.am2023-ct062.
• BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASISKumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Sharma A, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Matsutani M, Sales E, Sweed N, Dugan M, Kesari S. BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS. Neuro-Oncology 2022, 24: vii4-vii5. DOI: 10.1093/neuonc/noac209.015.
• NIMG-105. DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMASKim L, De Feyter H, de Graaf R, Fulbright R, Liu Y, Rothman D, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Corbin Z. NIMG-105. DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS. Neuro-Oncology 2022, 24: vii189-vii189. PMCID: PMC9660955, DOI: 10.1093/neuonc/noac209.723.
• TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with HyperostosisJin L, Vetsa S, Vasandani S, Nadar A, Youngblood M, Gupte T, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Gorelick E, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, Marianayagam N, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with Hyperostosis. Journal Of Neurological Surgery Part B Skull Base 2022, 83: s1-s270. DOI: 10.1055/s-0042-1743640.
• INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMABarak T, Hwang L, Chen J, Jin L, Miyagishima D, Yalcin K, Ogilvie S, Antonios J, Theriault B, Huttner A, McGuone D, Lifton N, Blondin N, Corbin Z, Zhang Y, Gunel M, Erson-Omay Z, Fulbright R, Tabar T, Moliterno-Gunel J. INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi107-vi107. PMCID: PMC8598632, DOI: 10.1093/neuonc/noab196.421.
• NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMASJin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.
• BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCERKumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.
• INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMABlondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.
• INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCERStuhlmiller T, Shapiro M, Wasserman A, Osking Z, Shrager J, Federowicz B, Warner M, Friedland J, Musella A, Blondin N, Fonkem E, Wong E, Kesari S. INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCER. Neuro-Oncology 2021, 23: vi113-vi113. DOI: 10.1093/neuonc/noab196.448.
• QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTSBlondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.
• ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Paul Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.
• ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMABarkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.
• INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS.Kumar Reddy N, Blondin N. INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS. Neuro-Oncology 2019, 21: vi135-vi135. PMCID: PMC6847258, DOI: 10.1093/neuonc/noz175.566.
• Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastomaKelly J, Proescholdt C, Blondin N. Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastoma. 2019, lb-163-lb-163. DOI: 10.1158/1538-7445.sabcs18-lb-163.
• Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastomaKelly J, Proescholdt C, Blondin N. Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastoma. Cancer Research 2019, 79: lb-163-lb-163. DOI: 10.1158/1538-7445.am2019-lb-163.
• ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.
• HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVALBlondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.
• QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENTBlondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.
• Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancementConnelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016, 16: 842. PMID: 27809808, PMCID: PMC5096303, DOI: 10.1186/s12885-016-2890-0.
• Primary CNS LymphomaBlondin N, Baehring J, Hochberg F. Primary CNS Lymphoma. 2014, 308-315. DOI: 10.1002/9781118589199.ch48.
• Diagnosis and management of periodic hypothermiaBlondin NA. Diagnosis and management of periodic hypothermia. Neurology Clinical Practice 2013, 4: 26-33. PMID: 29473588, PMCID: PMC5765588, DOI: 10.1212/01.cpj.0000437350.47610.3a.
• Anaplastic Gliomas Radiation, Chemotherapy, or Both?Blondin NA, Becker KP. Anaplastic Gliomas Radiation, Chemotherapy, or Both? Hematology/Oncology Clinics Of North America 2012, 26: 811-823. PMID: 22794285, DOI: 10.1016/j.hoc.2012.04.003.
• Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009)Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009). Neurology 2012, 78: in7-1.009-in7-1.009. DOI: 10.1212/wnl.78.1_meetingabstracts.in7-1.009.
• Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148)Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148). Neurology 2012, 78: p07.148-p07.148. DOI: 10.1212/wnl.78.1_meetingabstracts.p07.148.
• Paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone Mimicking Limbic EncephalitisBlondin NA, Vortmeyer AO, Harel NY. Paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone Mimicking Limbic Encephalitis. JAMA Neurology 2011, 68: 1591-1594. PMID: 22159058, DOI: 10.1001/archneurol.2011.876.
• Unilateral Tongue Atrophy and FasciculationBlondin NA, Huttner A, Baehring JM. Unilateral Tongue Atrophy and Fasciculation. JAMA Neurology 2011, 68: 1478-1478. PMID: 22084136, DOI: 10.1001/archneurol.2011.652.
• First-order Horner syndrome due to ipsilateral thalamic hemorrhageSawires M, Berek K, Blondin N, Schindler J. First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 77: 1019. PMID: 21893675, DOI: 10.1212/wnl.0b013e31822470d4.
• Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic HypothermiaBlondin NA, Greer DM. Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia. The Neurologist 2011, 17: 241-248. PMID: 21881465, DOI: 10.1097/nrl.0b013e318224ee0e.
• Teaching NeuroImages: First-order Horner syndrome due to ipsilateral thalamic hemorrhageBlondin NA, Schindler JL. Teaching NeuroImages: First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 76: e14. PMID: 21263131, DOI: 10.1212/wnl.0b013e31820882db.
• Thrombolysis in Right versus Left Hemispheric StrokeBlondin NA, Staff I, Lee N, McCullough LD. Thrombolysis in Right versus Left Hemispheric Stroke. Journal Of Stroke And Cerebrovascular Diseases 2010, 19: 269-272. PMID: 20471856, DOI: 10.1016/j.jstrokecerebrovasdis.2009.04.012.
• A case of lamotrigine-associated anticonvulsant hypersensitivity syndrome.Blondin NA, Zahedi S, Hale MS. A case of lamotrigine-associated anticonvulsant hypersensitivity syndrome. The Primary Care Companion For CNS Disorders 2008, 10: 249-50. PMID: 18615175, PMCID: PMC2446496, DOI: 10.4088/pcc.v10n0312b.